The company is a developer of an advanced therapeutic technology platform specializing in neuromuscular stimulation solutions designed to restore strength and function for patients with limited mobility. The internationally patented, FDA-registered product leverages space medicine technology invented by the company founder to serve as a countermeasure to disuse atrophy during long duration spaceflight. The company adapted this technology for use by frail older adults using funds from a National Institute on Aging (NIA) Small Business Innovation Research (SBIR) grant. The company has since evolved the internationally patented technology to enable controlled, patient specific neuromuscular stimulation that activates muscles passively and has been shown in multiple studies to significantly reduce pain and improve sensation / reduce neuropathy symptoms. To better deliver the neuromuscular stimulation, the company has incorporated AI-driven robotics to provide engaging, interactive workouts that patients enjoy. This advanced technology-based platform has been designed to collect treatment data that will be used for predictive analytics and to create AI-based user instructions that adapt treatment protocols in real-time to arrive at optimal patient outcomes. It provides safe, progressive treatments to the most vulnerable patients while unlocking new revenue streams and cost savings for customers. The platform has demonstrated strong clinical outcomes in over 2 dozen studies backed by NIH-funded research and pilot programs in hospitals, therapy gyms, skilled nursing, and senior living facilities. The value proposition for customers is strong (value of healthcare = outcomes x patient satisfaction x revenue / costs) because of the incredible outcomes and satisfaction achieved combined with treatments for lower functioning individuals being reimbursable by Medicare and insurance while also providing significant cost savings on the costliest population.

Operating on a capital-efficient, scalable model, the company employs commission-based sales and contract manufacturing to maintain lean overhead while enabling rapid expansion. With a growing clinical customer pipeline, a transition to recurring revenue through subscription and leasing models, and an increase in expected gross margins from 68% in year 1 to 90% in year 2, the business is positioned to scale within the $250B+ global medtech market. It is actively expanding into home health and veteran care channels and pursuing strategic partnerships to broaden its commercial footprint.

NDA is required to secure the comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.